Increased BDNF levels after electroconvulsive therapy in patients with major depressive disorder: A meta-analysis study

Rocha, Renan; Dondossola, Eduardo Ronconi; Grande, Antônio José; Colonetti, Tamy; Ceretta, Luciane Bisognin; Passos, Ives Cavalcante; Quevedo, João; Rosa, Maria Inês da

doi:10.1016/j.jpsychires.2016.08.004

Cited by 98 publications

(45 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Electroconvulsive therapy is often performed for pharmacological treatment-resistant MDD. Rocha et al conducted a meta-analysis to examine the association between serum/plasma level of BDNF and electroconvulsive therapy in patients with MDD ( 6 ). Electroconvulsive therapy significantly increased serum/plasma BDNF levels (SMD = 0.56; 95% CI = 0.17 to 0.96; p = 0.006; I 2 = 73%; N = 9, n = 414).…”

Section: Resultsmentioning

confidence: 99%

Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses

et al. 2018

View full text Add to dashboard Cite

Accumulating evidence suggests that brain-derived neurotrophic factor (BDNF) is associated with the pathophysiology of major depressive disorder (MDD). In this mini review, we explored the association between BDNF and MDD using meta-analytic evidence. Our findings indicated that the Val66Met polymorphism in the BDNF gene was not associated with MDD or hippocampal volume in patients with MDD. However, plasma/serum levels of BDNF were decreased in patients with acute MDD compared with healthy controls. Both antidepressant treatment and electroconvulsive therapy increased plasma and serum levels of BDNF in patients with MDD. Val66Met polymorphism in the BDNF gene was associated with an antidepressant response in patients with MDD. Taken together, we did not detect any plausible evidence regarding Val66Met polymorphism in the BDNF gene contributing to a risk of MDD. However, peripheral BDNF levels are decreased in patients with MDD, and the polymorphisms are associated with treatment response. In conclusion, BDNF is best understood to be a biomarker for the state of MDD and its treatment response rather than a risk factor for MDD.

show abstract

Section: Resultsmentioning

confidence: 99%

Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In addition, serum BDNF levels are abnormally low in patients with depressive disorder 17. Moreover, a meta-analysis suggests a potential role of BDNF as a marker of treatment response after treatment in patients with mood disorders,18 and another study showed that p-ERK levels decreased in depression rats 19. Therefore, the BDNF and p-ERK expressions were measured to ensure the success of depression rat models and to evaluate the therapeutic effect of CRPHF at the molecular level.…”

Section: Resultsmentioning

confidence: 99%

A novel herbal treatment reduces depressive-like behaviors and increases brain-derived neurotrophic factor levels in the brain of type 2 diabetic rats

Luo

Yuan

et al. 2016

NDT

View full text Add to dashboard Cite

BackgroundRadix Puerariae and hawthorn fruit have been demonstrated to treat diabetes. They offer potential benefits for preventing depression in diabetes.ObjectiveThe aim of this study was to investigate whether the combination of Radix Puerariae and hawthorn fruit (CRPHF) could prevent depression in a diabetic rat model generated by feeding the rats with a high-fat diet and a low-dose streptozotocin (STZ).MethodsThe CRPHF was provided by the Shanghai Chinese Traditional Medical University. Twenty-four rats were randomly divided into four groups: normal control, normal-given-CRPHF (NC), diabetic control, and diabetic-given-CRPHF (DC) groups. The type 2 diabetic model was created by feeding the rats with a high-fat diet for 4 weeks followed by injection of 25 mg/kg STZ. CRPHF was given at 2 g/kg/d to the rats of NC and DC groups by intragastric gavage daily for 4 weeks after the type 2 diabetic model was successfully created. Body weight, random blood glucose (RBG), oral glucose tolerance test, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured during the study. Depressive-like behavior was evaluated at the end of the treatment by using the open field test (OFT), the elevated plus-maze test (EPMT), locomotor activity test (LAT), and forced swimming test (FST). Levels of extracellular signal-regulated protein kinase (ERK) and brain-derived neurotrophic factor (BDNF) in the prefrontal cortex were evaluated by using Western blot.Results1) CRPHF reduced RBG and improved glucose tolerance in diabetic rats; 2) CRPHF reduced TC and TG but did not significantly change HDL-C or LDL-C in diabetic rats; 3) CRPHF reversed the loss in body weights observed in diabetic rats; 4) CRPHF reduced depressive-like behavior as measured by OFT, EPMT, LAT, and FST; 5) BDNF was upregulated, and ERK was activated in the prefrontal cortex of diabetic rats treated with CRPHF.ConclusionCRPHF has the potential of preventing depression in patients with diabetes.

show abstract

“…Elevated 35 and decreased 36 serum levels of BDNF have also been reported after ECT treatment. Changes in the plasma level of BDNF occur rapidly, and complete plasma/brain BDNF turnover takes approximately 6 min.…”

Section: Discussionmentioning

confidence: 96%

<p>BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study</p>

Huang¹,

Xiong²,

He³

et al. 2020

NDT

View full text Add to dashboard Cite

Objective: Ketamine and propofol have become increasingly popular in electroconvulsive therapy (ECT) anaesthesia. This study was conducted to examine whether changes in serum levels of brain-derived neurotrophic factor (BDNF) are associated with the antidepressant effects of ketofol, a combination of ketamine and propofol, in ECT for patients with treatment-resistant depression (TRD). Methods: Thirty patients with TRD (18-65 years) were enrolled and underwent eight ECT sessions with ketamine (0.5 mg/kg) plus propofol (0.5 mg/kg) (ketofol). Symptom severity was monitored using the 17-item Hamilton Depression Rating Scale (HAMD-17) and the Brief Psychiatric Rating Scale (BPRS), and serum levels of BDNF were examined by enzyme-linked immunosorbent assay (ELISA) at baseline and after 2, 4, and 8 ECT treatments. Serum levels of BDNF were also collected from thirty healthy controls. Results: At baseline, there were no significant differences in serum levels of BDNF between patients with TRD and healthy controls. The response and remission rates in patients with TRD were 100% (30/30) and 53.3% (16/30) after ECT treatment, respectively. Despite a significant reduction in HAMD-17 and BPRS scores after ECT, no changes in serum levels of BDNF were observed after ECT treatment when compared to baseline. No association was found between serum levels of BDNF and changes in illness severity. Conclusion: Serum levels of BDNF did not represent a suitable candidate biomarker for determining the antidepressant effects of ketofol during ECT for patients with TRD.

show abstract

Increased BDNF levels after electroconvulsive therapy in patients with major depressive disorder: A meta-analysis study

Cited by 98 publications

References 45 publications

Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses

Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses

A novel herbal treatment reduces depressive-like behaviors and increases brain-derived neurotrophic factor levels in the brain of type 2 diabetic rats

<p>BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study</p>

Contact Info

Product

Resources

About